UroGen Pharma Statistics
Total Valuation
UroGen Pharma has a market cap or net worth of $495.79 million. The enterprise value is $457.40 million.
| Market Cap | 495.79M |
| Enterprise Value | 457.40M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
| Earnings Date | May 9, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
UroGen Pharma has 34.12 million shares outstanding. The number of shares has increased by 26.43% in one year.
| Shares Outstanding | 34.12M |
| Shares Change (YoY) | +26.43% |
| Shares Change (QoQ) | -10.72% |
| Owned by Insiders (%) | 11.35% |
| Owned by Institutions (%) | 70.53% |
| Float | 24.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 5.99 |
| Forward PS | 4.91 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.42
| Current Ratio | 5.42 |
| Quick Ratio | 4.91 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.68 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -70.50% |
| Return on Capital (ROIC) | -191.72% |
| Revenue Per Employee | $417,742 |
| Profits Per Employee | -$516,384 |
| Employee Count | 198 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.87 |
Taxes
In the past 12 months, UroGen Pharma has paid $3.92 million in taxes.
| Income Tax | 3.92M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.80% in the last 52 weeks. The beta is 1.08, so UroGen Pharma's price volatility has been similar to the market average.
| Beta (1Y) | 1.08 |
| 52-Week Price Change | +25.80% |
| 50-Day Moving Average | 16.09 |
| 200-Day Moving Average | 15.10 |
| Relative Strength Index (RSI) | 48.64 |
| Average Volume (30 Days) | 377,135 |
Short Selling Information
The latest short interest is 4.19 million, so 12.27% of the outstanding shares have been sold short.
| Short Interest | 4.19M |
| Short Previous Month | 4.25M |
| Short % of Shares Out | 12.27% |
| Short % of Float | 17.18% |
| Short Ratio (days to cover) | 10.21 |
Income Statement
In the last 12 months, UroGen Pharma had revenue of $82.71 million and -$102.24 million in losses. Loss per share was -$3.55.
| Revenue | 82.71M |
| Gross Profit | 73.35M |
| Operating Income | -65.54M |
| Pretax Income | -98.32M |
| Net Income | -102.24M |
| EBITDA | -81.90M |
| EBIT | -83.61M |
| Loss Per Share | -$3.55 |
Balance Sheet
The company has $137.79 million in cash and $99.40 million in debt, giving a net cash position of $38.39 million or $1.13 per share.
| Cash & Cash Equivalents | 137.79M |
| Total Debt | 99.40M |
| Net Cash | 38.39M |
| Net Cash Per Share | $1.13 |
| Equity / Book Value | -65.21M |
| Book Value Per Share | -1.91 |
| Working Capital | 137.97M |
Cash Flow
In the last 12 months, operating cash flow was -$76.38 million and capital expenditures -$194,000, giving a free cash flow of -$76.57 million.
| Operating Cash Flow | -76.38M |
| Capital Expenditures | -194,000 |
| Free Cash Flow | -76.57M |
| FCF Per Share | -$2.66 |
Margins
Gross margin is 88.68%, with operating and profit margins of -79.23% and -123.61%.
| Gross Margin | 88.68% |
| Operating Margin | -79.23% |
| Pretax Margin | -118.87% |
| Profit Margin | -123.61% |
| EBITDA Margin | -99.02% |
| EBIT Margin | -101.08% |
| FCF Margin | -92.57% |
Dividends & Yields
UroGen Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.43% |
| Shareholder Yield | -26.43% |
| Earnings Yield | -20.62% |
| FCF Yield | -15.44% |
Analyst Forecast
The average price target for UroGen Pharma is $35.33, which is 143.15% higher than the current price. The consensus rating is "Buy".
| Price Target | $35.33 |
| Price Target Difference | 143.15% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 60.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
UroGen Pharma has an Altman Z-Score of -4.27 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.27 |
| Piotroski F-Score | 4 |